Connor Iapoce

At AAO 2024, Quan Dong Nguyen, MD, and Jia-Horung Hung, MD, discuss the Phase 2 Neptune trial investigating brepocitinib for active non-infectious uveitis.

At AAO 2024, Wykoff discussed first-time extended results from AMARONE showing Restoret’s effectiveness in improving outcomes for patients with DME and nAMD.

At AAO 2024, Kay presented an overview of gildeuretinol, an oral vitamin A derivative offering hope for patients with Stargardt disease.

On October 25, 2024, Kind Pharmaceutical announced receipt of FDA Orphan Drug Designation for AND017 in the treatment of sickle cell disease.

At AAO 2024, Khurana discussed rapid visual and structural gains for uveitic macular edema with vamikibart, paving the way for Phase 3 trials.

At AAO 2024, Garg describes an analysis of the Phase 2/3 PHOTON trial evaluating the effect of DME treatment history on aflibercept 8 mg and 2 mg outcomes.

Aquestive Therapeutics plans to submit an NDA for Anaphylm in Q1 2025 based on topline results from the Oral Allergy Syndrome challenge study.

At AAO 2024, HO described meaningful BCVA improvements in patients with retinitis pigmentosa observed through 2 years of the Phase 2b/3 RESTORE trial.

At AAO 2024, Kay describes encouraging interim safety and efficacy results from the ATSN-201 gene therapy trial in patients with X-linked retinoschisis.

At AAO 2024, Khanani discussed data showing a 97% reduction in annualized injection needs at 9 months with RGX-314 gene therapy.

Decreasing Vitamin A dimerization could be a potential mechanism to treat geographic atrophy, according to results from the two-year SAGA study at AAO 2024.

Pegcetacoplan injection showed increased benefit for subfoveal GA, with as few as 6 injections, over 3 years in the GALE extension trial.

At AAO 2024, Pearlman discusses how an innovative oral approach may provide an alternative pathway to existing treatments for DME.

Endophthalmitis incidence remained similar between face masking and non-face masking groups during anti-VEGF treatment.

At AAO 2024, Goldberg described pooled visual function data from 3 randomized, controlled clinical trials evaluating NT-501 for patients with MacTel.

At AAO 2024, Borkar discusses the visual acuity benefit of ONL1204 ophthalmic solution for patients with macula-off rhegmatogenous retinal detachment.

Multiwavelength photobiomodulation significantly lowered the risk of vision loss and geographic atrophy in eyes with dry age-related macular degeneration.

TRS01 eye drops demonstrate a positive benefit-risk profile for potential use as a first-line treatment in anterior non-infectious uveitis.

The 24-month data showed a notable response rate in study eyes treated with a high dose of AGTC-501, with a generally safe and tolerable clinical profile.

At AAO 2024, Do describes the durable vision gains and anatomic improvements achieved with aflibercept 8 mg for DME over 3 years of the PHOTON trial.

In the Phase 2 ARCHER trial, ANX007 protected against visual acuity loss and remained well-tolerated for patients with geographic atrophy.

At AAO 2024, Schneider explains the pivotal trial outcomes of AI-based home OCT, compared with standard in-office OCT scans.

At AAO 2024, Cunningham describes the clinical response and safety of faricimab (Vabysmo) in underrepresented populations with diabetic macular edema.

A history of anti-VEGF injections for retinal conditions may increase the incidence of complications after cataract surgery.

OCU400 gene therapy remained safe and tolerable across different mutation and dose cohorts in retinitis pigmentosa and Leber congenital amaurosis.

Incorporating baked milk products into a regular diet may improve growth and quality of life in milk-allergic children.

Early epinephrine intervention at home can potentially successfully treat anaphylaxis in children without further treatment in a hospital setting.

Increased serum TBA levels at baseline significantly raised the risk of HCC development in patients with multi-etiology cirrhosis.

SGLT2 inhibitors appeared effective in improving hepatic inflammation and fibrosis indices in patients with type 2 diabetes and suspected MASLD.

Anemia could be a reliable sign of all-cause mortality in patients with heart failure.